337 related articles for article (PubMed ID: 32441252)
1. Parallel CRISPR-Cas9 screens clarify impacts of p53 on screen performance.
Bowden AR; Morales-Juarez DA; Sczaniecka-Clift M; Agudo MM; Lukashchuk N; Thomas JC; Jackson SP
Elife; 2020 May; 9():. PubMed ID: 32441252
[TBL] [Abstract][Full Text] [Related]
2. Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.
Song CQ; Li Y; Mou H; Moore J; Park A; Pomyen Y; Hough S; Kennedy Z; Fischer A; Yin H; Anderson DG; Conte D; Zender L; Wang XW; Thorgeirsson S; Weng Z; Xue W
Gastroenterology; 2017 Apr; 152(5):1161-1173.e1. PubMed ID: 27956228
[TBL] [Abstract][Full Text] [Related]
3. p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells.
Ihry RJ; Worringer KA; Salick MR; Frias E; Ho D; Theriault K; Kommineni S; Chen J; Sondey M; Ye C; Randhawa R; Kulkarni T; Yang Z; McAllister G; Russ C; Reece-Hoyes J; Forrester W; Hoffman GR; Dolmetsch R; Kaykas A
Nat Med; 2018 Jul; 24(7):939-946. PubMed ID: 29892062
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Editing of the
Mirgayazova R; Khadiullina R; Chasov V; Mingaleeva R; Miftakhova R; Rizvanov A; Bulatov E
Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32630614
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/CAS9-based DNA damage response screens reveal gene-drug interactions.
Su D; Feng X; Colic M; Wang Y; Zhang C; Wang C; Tang M; Hart T; Chen J
DNA Repair (Amst); 2020 Mar; 87():102803. PubMed ID: 31991288
[TBL] [Abstract][Full Text] [Related]
6. CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response.
Haapaniemi E; Botla S; Persson J; Schmierer B; Taipale J
Nat Med; 2018 Jul; 24(7):927-930. PubMed ID: 29892067
[TBL] [Abstract][Full Text] [Related]
7. SliceIt: A genome-wide resource and visualization tool to design CRISPR/Cas9 screens for editing protein-RNA interaction sites in the human genome.
Vemuri S; Srivastava R; Mir Q; Hashemikhabir S; Dong XC; Janga SC
Methods; 2020 Jun; 178():104-113. PubMed ID: 31494246
[TBL] [Abstract][Full Text] [Related]
8. Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting.
Aguirre AJ; Meyers RM; Weir BA; Vazquez F; Zhang CZ; Ben-David U; Cook A; Ha G; Harrington WF; Doshi MB; Kost-Alimova M; Gill S; Xu H; Ali LD; Jiang G; Pantel S; Lee Y; Goodale A; Cherniack AD; Oh C; Kryukov G; Cowley GS; Garraway LA; Stegmaier K; Roberts CW; Golub TR; Meyerson M; Root DE; Tsherniak A; Hahn WC
Cancer Discov; 2016 Aug; 6(8):914-29. PubMed ID: 27260156
[TBL] [Abstract][Full Text] [Related]
9. CRISPR screens are feasible in TP53 wild-type cells.
Brown KR; Mair B; Soste M; Moffat J
Mol Syst Biol; 2019 Aug; 15(8):e8679. PubMed ID: 31464370
[TBL] [Abstract][Full Text] [Related]
10. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
11. Boosting targeted genome editing using the hei-tag.
Thumberger T; Tavhelidse-Suck T; Gutierrez-Triana JA; Cornean A; Medert R; Welz B; Freichel M; Wittbrodt J
Elife; 2022 Mar; 11():. PubMed ID: 35333175
[TBL] [Abstract][Full Text] [Related]
12. High content analysis platform for optimization of lipid mediated CRISPR-Cas9 delivery strategies in human cells.
Steyer B; Carlson-Stevermer J; Angenent-Mari N; Khalil A; Harkness T; Saha K
Acta Biomater; 2016 Apr; 34():143-158. PubMed ID: 26747759
[TBL] [Abstract][Full Text] [Related]
13. Identification of functional regulatory elements in the human genome using pooled CRISPR screens.
Borys SM; Younger ST
BMC Genomics; 2020 Jan; 21(1):107. PubMed ID: 32005150
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9 treatment causes extended TP53-dependent cell cycle arrest in human cells.
Geisinger JM; Stearns T
Nucleic Acids Res; 2020 Sep; 48(16):9067-9081. PubMed ID: 32687165
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the CRISPR/Cas9 directed mutant TP53 gene repairing effect in human prostate cancer cell line PC-3.
Batır MB; Şahin E; Çam FS
Mol Biol Rep; 2019 Dec; 46(6):6471-6484. PubMed ID: 31571107
[TBL] [Abstract][Full Text] [Related]
16. TP53-dependent toxicity of CRISPR/Cas9 cuts is differential across genomic loci and can confound genetic screening.
Álvarez MM; Biayna J; Supek F
Nat Commun; 2022 Aug; 13(1):4520. PubMed ID: 35927263
[TBL] [Abstract][Full Text] [Related]
17. No apparent p53 activation in CRISPR-engineered gene-edited rabbits.
Zhang T; Li J; Wang T; Zhao F; Sui T
J Cell Mol Med; 2021 Nov; 25(21):10313-10317. PubMed ID: 34609046
[TBL] [Abstract][Full Text] [Related]
18. Pooled Lentiviral CRISPR-Cas9 Screens for Functional Genomics in Mammalian Cells.
Aregger M; Chandrashekhar M; Tong AHY; Chan K; Moffat J
Methods Mol Biol; 2019; 1869():169-188. PubMed ID: 30324523
[TBL] [Abstract][Full Text] [Related]
19. Cas9 activates the p53 pathway and selects for p53-inactivating mutations.
Enache OM; Rendo V; Abdusamad M; Lam D; Davison D; Pal S; Currimjee N; Hess J; Pantel S; Nag A; Thorner AR; Doench JG; Vazquez F; Beroukhim R; Golub TR; Ben-David U
Nat Genet; 2020 Jul; 52(7):662-668. PubMed ID: 32424350
[TBL] [Abstract][Full Text] [Related]
20. GenomeCRISPR - a database for high-throughput CRISPR/Cas9 screens.
Rauscher B; Heigwer F; Breinig M; Winter J; Boutros M
Nucleic Acids Res; 2017 Jan; 45(D1):D679-D686. PubMed ID: 27789686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
